Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus mRNAs, resulted in sustained loss of hepatitis B surface antigen and HBV DNA in 9 to 10% of participants with chronic HBV infection.

Uloženo v:

Podrobná bibliografie
Vydáno v:	The New England journal of medicine Ročník 387; číslo 21; s. 1957 - 1968
Hlavní autoři:	Yuen, Man-Fung, Lim, Seng-Gee, Plesniak, Robert, Tsuji, Keiji, Janssen, Harry L.A., Pojoga, Cristina, Gadano, Adrian, Popescu, Corneliu P., Stepanova, Tatyana, Asselah, Tarik, Diaconescu, Gheorghe, Yim, Hyung Joon, Heo, Jeong, Janczewska, Ewa, Wong, Alexander, Idriz, Nevin, Imamura, Michio, Rizzardini, Giuliano, Takaguchi, Koichi, Andreone, Pietro, Arbune, Manuela, Hou, Jinlin, Park, Sung Jae, Vata, Andrei, Cremer, Jennifer, Elston, Robert, Lukić, Tamara, Quinn, Geoff, Maynard, Lauren, Kendrick, Stuart, Plein, Helene, Campbell, Fiona, Paff, Melanie, Theodore, Dickens
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Massachusetts Medical Society 24.11.2022
Témata:	Alanine transaminase Antigens Antisense oligonucleotides Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Antiviral drugs Chronic infection DNA, Viral - blood Fever Gastroenterology Gastroenterology General Genetics Hepatitis Hepatitis B Hepatitis B e Antigens - blood Hepatitis B surface antigen Hepatitis B Surface Antigens - blood Hepatitis B virus - genetics Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - virology Humans Hypothesis testing Infections Infectious Disease Injections, Subcutaneous International organizations Laboratories Liver cancer Liver Disease Liver diseases Nucleoside analogs Nucleotide analogs Oligonucleotides, Antisense - administration & dosage Oligonucleotides, Antisense - adverse effects Oligonucleotides, Antisense - therapeutic use Placebos Response rates RNA Therapeutics RNA, Messenger - drug effects RNA, Viral - drug effects Treatment Outcome Viral Infections
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus mRNAs, resulted in sustained loss of hepatitis B surface antigen and HBV DNA in 9 to 10% of participants with chronic HBV infection.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2210027